DIGITAL QUALITY ASSOCIATES
WHERE EXPERIENCE COUNTS

Part 1: The Evolution of IT Quality and Validation in Clinical Trials: Understanding ICH E6(R3) GCP Guidelines and Related Regulations

Introduction

The clinical trial landscape has undergone significant transformation with digital technology becoming increasingly central to trial design, data collection, and management. The recently updated International Council for Harmonisation (ICH) Good Clinical Practice (GCP) E6(R3) guideline, adopted in December 2024 and coming into effect July 2025, represents a major evolution in how regulatory bodies expect sponsors and investigators to manage computerized systems and data integrity in clinical trials.

This comprehensive revision reflects the growing recognition that proper IT validation and quality management are essential to ensuring participant safety and data reliability. As clinical trials incorporate more advanced technologies—from electronic data capture to wearable devices and decentralized trial elements—the need for robust IT governance has never been more critical.

This article examines the key IT quality and validation requirements outlined in ICH E6(R3), contextualizes them within the broader regulatory framework, and provides practical guidance for implementation. Understanding these requirements is essential for any organization conducting or supporting clinical trials in today's increasingly digital research environment.

Computerized Systems Validation: A Risk-Based Approach

Core Principles in ICH E6(R3)

Section 4.3.4 of ICH E6(R3) outlines a comprehensive approach to computerized systems validation that emphasizes proportionality and risk assessment. The guideline states that "The responsible party is responsible for the validation status of the system throughout its life cycle. The approach to validation of computerised systems should be based on a risk assessment that considers the intended use of the system; the purpose and importance of the data/record that is collected/generated, maintained and retained in the system; and the potential of the system to affect the well-being, rights and safety of trial participants and the reliability of trial results" (section 4.3.4(a)).

This risk-based approach represents a significant shift from earlier versions of the guideline. Rather than prescribing specific validation methodologies for all systems, ICH E6(R3) encourages organizations to tailor their validation efforts based on the criticality of the system and its data. For example, a randomization system would require more intensive validation than a simple document management system.

The guideline also addresses validation requirements for different types of systems, stating: "Different degrees of validation may be needed for bespoke systems, systems designed to be configured or systems where no alterations are needed" (section 4.3.4(e)).

Validation should demonstrate that "the system conforms to the established requirements for completeness, accuracy and reliability and that its performance is consistent with its intended purpose" (section 4.3.4(b)). The guideline specifically requires that "Systems should be appropriately validated prior to use" (section 4.3.4(c)).

For critical functionality, validation should include "defining the requirements and specifications for the system and their testing, along with the associated documentation, to ensure the system is fit for purpose, especially for critical functionality, such as randomisation, dosing and dose titrations and reductions, and collection of endpoint data" (section 4.3.4(h)).

Integration with Other Regulatory Frameworks

This risk-based validation approach aligns with other regulatory guidance documents, including:

1. FDA 21 CFR Part 11 (Electronic Records; Electronic Signatures): While ICH E6(R3) provides general principles, Part 11 offers specific requirements for electronic records and signatures in FDA-regulated clinical trials. Part 11 compliance remains essential for studies submitted to the FDA.

2. EMA Reflection Paper on Expectations for Electronic Source Data and Data Transcribed to Electronic Data Collection Tools in Clinical Trials: This European Medicines Agency document complements ICH E6 (R3) by providing more detailed expectations regarding electronic source data.

3. MHRA 'GXP' Data Integrity Guidance and Definitions: The UK Medicines and Healthcare products Regulatory Agency guidance provides detailed expectations on data integrity that extend beyond the ICH framework and addresses ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available).

4. PIC/S Guidance on Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments: While primarily focused on manufacturing, this Pharmaceutical Inspection Co-operation Scheme guidance contains principles applicable to clinical trial data management.

Implementation Considerations

Organizations implementing the validation requirements in ICH E6(R3) should consider:

1. Developing a validation risk assessment methodology that categorizes systems based on their impact on participant safety and data reliability

2. Creating validation plans that are proportionate to the identified risks

3. Documenting validation activities with sufficient detail to demonstrate that the system is fit for purpose

4. Implementing change control procedures that include appropriate revalidation based on the nature of the change, as indicated in section 4.3.4(c): "Subsequent changes to the system should be validated based on risk and should consider both previously collected and new data in line with change control procedures."

5. Ensuring that validation documentation is maintained throughout the system lifecycle

Look out for Part 2

Coming soon